At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Apr 27, 2026 at 16:05 ET
Structure Therapeutics announced multiple presentations at the ADA 86th Scientific Sessions, including an oral presentation of Phase 2b ACCESS trial data for aleniglipron. No clinical results were disclosed in this press release.
- Five presentations at ADA 2026 including oral on ACCESS Phase 2b trial of aleniglipron
- Combination therapy data with oral GLP-1 and amylin receptor agonists in NHPs
- Lower starting dose data to improve GI tolerability
- No clinical efficacy or safety data released in this announcement
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access